JP Morgan Resumes Coverage of Hims & Hers Health with Neutral Rating Amid GLP-1 Compounding Challenges
Following a suspension in June, JP Morgan has resumed coverage on Hims & Hers Health (HIMS) and assigned it a neutral rating. The bank cited headwinds facing the company's GLP-1 compounding business as a key concern. Previously rated overweight by the firm, this downgrade reflects growing challenges for Hims & Hers in maintaining growth within its compounded medication segment. The telehealth provider has seen increased scrutiny and regulatory pressure on its compounded drugs, particularly those related to weight loss treatments like semaglutide (GLP-1 agonists). These compounding operations have been a significant revenue driver but are now under threat due to competition from branded alternatives. JP Morgan's neutral stance suggests the firm sees limited upside in HIMS for the near term. The market reaction has been mixed, with investors weighing concerns over regulatory risks and competitive pressures against potential long-term growth opportunities outside of compounding.
